Show simple item record

Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment

dc.contributor.authorAcharya, Nandini
dc.contributor.authorMadi, Asaf
dc.contributor.authorZhang, Huiyuan
dc.contributor.authorKlapholz, Max
dc.contributor.authorEscobar, Giulia
dc.contributor.authorDulberg, Shai
dc.contributor.authorChristian, Elena
dc.contributor.authorFerreira, Michelle
dc.contributor.authorDixon, Karen O
dc.contributor.authorFell, Geoffrey
dc.contributor.authorTooley, Katherine
dc.contributor.authorMangani, Davide
dc.contributor.authorXia, Junrong
dc.contributor.authorSinger, Meromit
dc.contributor.authorBosenberg, Marcus
dc.contributor.authorNeuberg, Donna
dc.contributor.authorRozenblatt-Rosen, Orit
dc.contributor.authorRegev, Aviv
dc.contributor.authorKuchroo, Vijay K
dc.contributor.authorAnderson, Ana C
dc.date.accessioned2021-10-27T19:56:52Z
dc.date.available2021-10-27T19:56:52Z
dc.date.issued2020
dc.identifier.urihttps://hdl.handle.net/1721.1/133832
dc.description.abstract© 2020 Elsevier Inc. Acharya et al. uncover a gradient of increasing glucocorticoid signaling from naïve to dysfunctional CD8+ tumor-infiltrating lymphocytes. This gradient regulates effector transition and development of dysfunction. Glucocorticoid is produced locally by tumor-associated monocyte-macrophage lineage cells, and presence of active glucocorticoid signaling associates with poor response to immune checkpoint blockade.en_US
dc.language.isoen
dc.publisherElsevier BVen_US
dc.relation.isversionof10.1016/J.IMMUNI.2020.08.005en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleEndogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironmenten_US
dc.typeArticleen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biology
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MIT
dc.contributor.departmentLudwig Center for Molecular Oncology (Massachusetts Institute of Technology)
dc.contributor.departmentHoward Hughes Medical Institute
dc.relation.journalImmunityen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2021-09-20T14:33:35Z
dspace.orderedauthorsAcharya, N; Madi, A; Zhang, H; Klapholz, M; Escobar, G; Dulberg, S; Christian, E; Ferreira, M; Dixon, KO; Fell, G; Tooley, K; Mangani, D; Xia, J; Singer, M; Bosenberg, M; Neuberg, D; Rozenblatt-Rosen, O; Regev, A; Kuchroo, VK; Anderson, ACen_US
dspace.date.submission2021-09-20T14:33:38Z
mit.journal.volume53en_US
mit.journal.issue3en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail
Name:
nihms-1629126.pdf
Size:
3.626Mb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following Collection(s)

Show simple item record